Sponsors (21)
The bill expands access to genome sequencing for Medicaid-enrolled children and increases transparency and oversight, improving diagnostic access but raising Medicaid costs, implementation burdens, and risks of under-reimbursement or overuse if payment levels and safeguards are not well-designed.
Medicaid-enrolled children and youth with suspected genetic disorders will gain coverage for whole-genome or whole-exome sequencing as a covered medical service, increasing access to diagnostic testing and potentially earlier diagnosis and treatment.
States must pay separately for sequencing rather than bundling it into other payments, improving reimbursement transparency and creating stronger financial incentives for labs and providers to offer sequencing to Medicaid patients.
HHS-led outreach and stakeholder convenings, a GAO assessment, and public reporting on state payment amounts, utilization, and outcomes will identify implementation barriers, produce recommendations, and increase transparency for families and policymakers.
Expanding Medicaid-covered sequencing will increase Medicaid spending, which could pressure state budgets, raise taxpayer costs, or require additional federal/state funding adjustments.
If provider payment rates are set too low or misaligned with market costs, labs and genetic counselors may face inadequate reimbursement, limiting provider participation and reducing practical access despite the coverage mandate.
Designating sequencing as a 'first-tier' test in specified cases could increase utilization and risk overuse in borderline cases if clinical criteria and prior-authorization safeguards are not well-defined.
Based on analysis of 2 sections of legislative text.
Requires Medicaid coverage and separate payment for whole genome and exome sequencing as a first‑tier diagnostic test for children with suspected genetic or unexplained conditions, with HHS and GAO reporting requirements.
Introduced January 15, 2026 by Scott Peters · Last progress January 15, 2026
Adds whole genome sequencing (WGS) and whole exome sequencing (WES) to the list of services that Medicaid must cover for children when ordered as a first‑tier test by an authorized provider for suspected genetic disorders, rare diseases, or unexplained conditions (including congenital anomalies, global developmental delay, or intellectual disability). It requires separate payment (not bundled) for these tests and defines sequencing and associated analysis and reporting. Directs the Department of Health and Human Services to convene stakeholders, conduct outreach, and publish a report on State payment and utilization within two years, and directs the Government Accountability Office to collect stakeholder feedback, assess impacts (including prior authorization, genetic counseling workforce and reimbursement, and laboratory payment alignment), and make recommendations within two years. Changes take effect January 1, 2027.